influenzae.b were 0.312 and 0.625 ,jg/ml, respectively. Sixteen of 18 isolates of H. influenzae b and S. pneumoniae were killed by 2.5 ,ug of cefoxitin per ml. Mean levels in CSF peaked at 1 h at 6 and 4.9 jig/ml on days 5 and 10, respectively. CSF levels on days 5 and 10 were -twice the median minimal inhibitory and bactericidal concentration in 20 and 18 patients, respectively. However, bacterial levels in CSF were -2.5 xg/ml in only 11 of 23 patients on days 5 and 10. No significant adverse effects were found. These data indicate that at this dosage, cefoxitin may not reach levels in the CSF required for killing all susceptible strains of H. influenzae b and S. pneumoniae.
Cefoxitin is a semisynthetic cefamycin, active in vitro against common meningeal pathogens such as Neisseria meningitidis, Streptococcus pneumoniae, and ampicillin-susceptible and -resistant strains of Haemophilus influenzae type b (1, 2, 6, 8, 14, 17) . The results of clinical trials in adults (6, 12, 13) and children (2, 8) have shown that this drug is safe and effective against infections with S. pneumoniae and H. influenzae b outside the central nervous system. Thus, cefoxitin has the potential for single-drug therapy for infants and children with suspected bacterial meningitis provided it effectively penetrates into the cerebrospinal fluid (CSF).
Available data are limited on the penetration of cefoxitin into the CSF (3, 7, 11) . Galvao and co-workers (3) gave three 2-g doses of cefoxitin, in addition to ampicillin or.penicillin, to 25 adult patients with purulent meningitis. The mean peak level 4 h after the third dose was 6.9 ,ug of cefoxitin per ml. Humbert and co-workers (7) reported CSF levels in patients with bacterial meningitis ranging from 2.9 to 4.7 ,ug/ml, depending upon the day of treatment and the time after the last dose of cefoxitin. Liu et al. (11) measured levels ranging from 1.25 to 5.0 ,ug/ml after multiple 2-g doses of cefoxitin in five adult patients who had no evidence of meningeal inflammation.
These tested were inhibited and killed by c2.5 ,ug/ml. Concentrations of cefoxitin in serum and CSF were determined on days 5 and 10 of therapy for 23 patients (Fig. 1) . One patient had no detectcefoxitin content by the microbioassay technique able cefoxitin in his CSF obtained 0.5 h after the ,imon and Yin (16), using E. coli strain MB 3804 as test organism. Pilot experiments showed that cetin levels in CSF or serum were not affected by the greatest 1 h after the third dose on both days. icillinase treatment. Levels as low as 0.3 pg of CSF levels on day 5 remained above the median xitin per ml were reliably detected. Samples were MIC and MBC of the H. influenzae b isolates for ed at -70°C and assayed within 3 days of collec-22 patients. On day 10, CSF levels of two patients were less than the median MBC. Howerum concentrations were plotted against time by ever, only 11 patients had levels on both days g a semilogarithmic scale, and half-life was calcu--2.5 jxg/ml, which killed approximately 90% of d when levels were declining exponentially during isolates in vitro. By the paired t-test (two-tailed), elimination phase. The formula used was ln 2/K, C l :re isth¢enaton atecontantrepeseted CSF levels on day S did not differ significantly ,re K is the elimination rate constant represented fo hs ndy1 P>01) the slope of the regression line determined by the the dose on both days (Fig. 2) . No significant 'SF samples were cultured on 5% sheep blood agar difference (P = 0.19) was found when the ratios on chocolate agar and thioglycolate broth. Isolates of the CSF level to the concomitant serum level e identified by standard techniques (10) . H. in on day 5 were compared with those on day 10.
nzae b isolates were tested for 1-lactamase proThe plasma clearance was significantly greattion by the rapid method of Jorgensen et al. (9) .
MICs of cefoxitin for bacterial pathogens were er on day 10 than on day 5 (P < 0.01), but serum rmined by broth dilution, using Mueller-Hinton half-lives and volumes of distribution did not h (Difco) with 2% supplement C (Difco). Twofold significantly differ on the 2 days (Table 1) .
centrations of cefoxitin from 20 to 0.019 ,ug/ml Sixteen patients had no adverse effects. One e prepared in 1-ml samples, and an inoculum of patient had a maculopapular skin rash during the roximately 105 organisms was added. The MIC first course of therapy, which did not recur after the smallest concentration of cefoxitin preventing the second course; this patient also had a tranble growth after incubation at 37°C for 18 h. sient elevation of SGOT to 159 U/ml. Six other imal bactericidal concentrations (MBC) were de-patients had transiently elevated SGOT levels nined by subculturing all clear tubes onto chocolate ranging from 68 to 354 U/mi (normal, 0 to 40 U! he statistical tests used were chi-square analysis ml). The SQOT levels decreased despite the the two-tailed Student's t test, comparing the continued administration of cefoxitin, and no ns of two small samples from normal populations patient had jaundice. One infant had a transient eosinophilia. The drug was not discontinued in any patient because of an adverse effect. No patient had phlebitis. DISCUSSION In this study, the CSF levels were greater than the median MBC in the majority of patients in our study. However, several isolates required substantially more cefoxitin for a bactericidal effect. Levels -2.5 ,ug/ml, which would kill approximately 90% of isolates, were achieved in only 11 of 23 patients on days 5 and 10 of therapy. Thus, these data suggest that CSF penetration at this dosage may not be adequate to kill all bacterial isolates in vivo.
The dosage used in this study of 75 mg of cefoxitin per kg every 6 hours was larger than those previously reported (2, 8) . However, the half-lives and volumes of distribution were comparable with those previously reported (2) for a smaller dosage (37.5 mg/kg) every 6 hours. Although one-third of the patients had "side-effects", these were mainly transient elevations in SGOT levels, which resolved despite continued administration of cefoxitin. No patient had a serious reaction which resulted in discontinuing the drug.
These data indicate that CSF penetration of multiple doses of cefoxitin in infants and children with bacterial meningitis is comparable to that previously reported in adult patients (3, 7, 11) . Although the dosage used had no significant adverse effects, these levels in CSF may not be capable of killing all bacterial pathogens. Thus, these data do not support the evaluation of cefoxitin in a clinical trial as single-drug therapy for pediatric patients with meningitis.
